We look forward to filing for market approval in China as soon as possible to bring HRS9531 to patients struggling with obesity and overweight. We commend our colleagues at Hengrui for these impressive Phase 3 clinical results, building on the strong momentum behind HRS9531 (KAI-9531)
There is no flat per-compound pricing
They are the reason the schedule is a guide, not a mandate
In a vicious cycle, the intricate interaction between dietary components and other variables affects the gut microbiota and pathogenesis of many cardiovascular diseases as shown in Figure 7 (168)
It is a once-weekly injectable therapy designed to improve glycemic control in adults whose blood sugar is not adequately controlled with diet, exercise, or other antidiabetic medications
While this is highly effective for managing blood sugar and supporting weight loss, it can overwhelm the digestive system in the early stages of treatment